Tick-Borne Encephalitis Vaccine Effectiveness and Impact in Slovenia, 2019–2024
Pathogens · 07.05.2026 · 15 (5) · 503
DOI: 10.3390/pathogens15050503 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathogens, online erschienen am 07.05.2026. Verfasst von Jan Kordež und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medical and Scientific Affairs, Pfizer, SI-1000 Ljubljana, Slovenia. Hauptthemen laut MEDLINE: Encephalitis, Tick-Borne, Viral Vaccines, Vaccine Efficacy, Encephalitis Viruses, Tick-Borne. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Slovenia has a high tick-borne encephalitis (TBE) incidence and TBE vaccination is recommended for all residents ≥1 year-of-age. Despite widespread TBE vaccine use in Slovenia, TBE vaccine effectiveness (VE) has not been reported for Slovenia. We defined individuals who received ≥3 TBE vaccine doses in accordance with the recommended vaccination schedule as fully vaccinated. Using the screening method, TBE VE was determined by comparing the proportions of TBE cases and survey respondents who were fully vaccinated. TBE incidence and VE were used to estimate the number of TBE cases prevented by TBE vaccination. Of 637 surveillance-reported TBE cases in 2019–2024, 332 (52.1%) had a known vaccination history. Of these 332 TBE cases, 322 (97.0%) were unvaccinated and 10 (3.0%) received ≥1 doses of a TBE vaccine. Among 25,242 persons surveyed with known TBE vaccination history, 57.9% were unvaccinated. VE of ≥3 TBE doses for the prevention of TBE was 93.4% (84.0–97.3%). TBE vaccination prevented 426 TBE cases in 2019–2024. If the entire population was vaccinated against TBE, vaccination would have prevented 994 TBE cases in 2019−2024. TBE vaccination in Slovenia was highly effective, preventing hundreds of TBE cases a year. Most of the Slovenian population, however, is not vaccinated against TBE. To prevent additional TBE cases in Slovenia, further efforts are needed to enhance TBE vaccine uptake.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical and Scientific Affairs, Pfizer, SI-1000 Ljubljana, Slovenia.
- Medical Evidence Development, Bacterial Vaccines Real-World Evidence and Epidemiology, Pfizer, Collegeville, PA 19426, USA.
- Medical Affairs Evidence Generation Statistics, Pfizer Research and Development, Collegeville, PA 19426, USA.
- Medical Evidence Development, Bacterial Vaccines Real-World Evidence and Epidemiology, Pfizer, New York, NY 19426, USA.
- Medical Evidence Generation, Bacterial Vaccines Real-World Evidence and Epidemiology, Pfizer, Collegeville, PA 19426, USA.
- Medical Evidence Development, Vaccines, Integrated Evidence Generation, Pfizer, Collegeville, PA 19426, USA.
ORCID-Profile: Frederick J Angulo, Pingping Zhang, Alexander Davidson, Lisa R Harper, Andreas Pilz, Hannah Gould
Förderung
- Pfizer
Zitieren
APA
Kordež, J., Angulo, F. J., Zhang, P., Davidson, A., Edwards, J., Harper, L. R., Pilz, A., & Gould, H. (2026). Tick-Borne Encephalitis Vaccine Effectiveness and Impact in Slovenia, 2019–2024. Pathogens, 15(5), 503. https://doi.org/10.3390/pathogens15050503
Vancouver
Kordež J, Angulo FJ, Zhang P, Davidson A, Edwards J, Harper LR, et al. Tick-Borne Encephalitis Vaccine Effectiveness and Impact in Slovenia, 2019–2024. Pathogens. 2026;15(5):503. doi:10.3390/pathogens15050503
BibTeX
@article{Korde2026,
author = {Kordež, Jan and Angulo, Frederick J and Zhang, Pingping and Davidson, Alexander and Edwards, Juanita and Harper, Lisa R and Pilz, Andreas and Gould, Hannah},
title = {Tick-Borne Encephalitis Vaccine Effectiveness and Impact in Slovenia, 2019–2024},
journal = {Pathogens},
year = {2026},
volume = {15},
number = {5},
pages = {503},
doi = {10.3390/pathogens15050503}
}
EUVIMED